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ABSTRACT
Background
Streptococcus  pneumoniae is  a  leading  cause  of  morbidity  and  mortality  in  children 
worldwide.  Although  the  7-valent  pneumococcal  conjugate  vaccine  (PCV7)  has  been 
successful in controlling pneumococcal disease, some disease-causing serotypes are not 
covered by this vaccine. We report the infant series results of a randomised, double-blind, 
active-controlled  study  of  a  13-valent-pneumococcal  vaccine  (PCV13),  containing 
polysaccharides  from  serotypes  1,  3,  4,  5,  6A,  6B,  7F,  9V,  14,  18C,  19A,  19F,  23F 
individually conjugated to CRM197.
Methods
278 healthy infants aged 6 -14 weeks were enrolled and randomised 1:1 to receive PCV13 
or  PCV7  at  2  and  4  months.  Participants  received  serogroup  C  meningococcal  (MenC) 
vaccine  at  2  and  4  months  and  DTaP-IPV-Hib vaccine  at  age  2,  3,  and  4  months. 
Concomitant antibody responses in both groups and PCV13 responses in the PCV13 group 
were assessed at 5 months.
Results
Concomitant  antibody  responses  were  comparable  in  the  2  groups.  Anti-PRP  IgG 
concentration ≥ 0.15 μg/ml was achieved by 96.5% of the PCV13 group and 98.1% of the 
PCV7 group. MenC SBA titres of ≥ 1:8 were achieved by 99.2% of participants in both. All 
participants in both groups achieved IgG concentrations ≥ 5 EU/mL for pertussis antigens 
PT, FHA and Pertactin. The proportion of participants in the PCV13 group with serotype 
specific  IgG  concentrations  ≥0.35µg/mL  ranged  from  40.7%  (serotype  6B)  to  96.3% 
(serotype 1). PCV7 and PCV13 were well tolerated with comparable reactogenicity profiles.
Conclusions
Immunogenicity of concomitant antigens is comparable when administered with either PCV7 
or PCV13 in a UK primary infant series.
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INTRODUCTION
• The 7 valent pneumococcal conjugate vaccine (PCV7) has successfully reduced invasive 
pneumococcal disease in the countries where it has been introduced1.
• Significant disease causing serotypes such as serotypes 1, 3 and 19A are not included in 
this vaccine, with a suboptimal coverage of the global pneumococcal disease burden2.
• A novel 13 valent pneumococcal conjugate vaccine (PCV13) has been developed and 
was assessed in this multi-centred double blind randomised controlled trial 
• The study was sponsored by Wyeth Vaccines
OBJECTIVES
• To  evaluate  the  proportion  of  participants  achieving  predetermined  thresholds  for 
concomitant antigens 1 month after the infant series 
• To evaluate the safety and reactogenicity of PCV13
• To assess the antibody response of participants receiving a 2 and 4 month course of PCV 13
CONCLUSIONS AND DISCUSSION
• PCV13 was immunogenic and well tolerated when given as part of  the UK infant vaccine course.
• The  percentages  of  participants  achieving  the  thresholds  of  response  for  the  concomitant  
antigens were comparable between the two groups.
• PCV13  vaccination  at  2  and  4  months  resulted  in  78.5  - 96.3%  of  vaccinees achieving  the 
correlate of protection for the 6 additional serotypes not contained in PCV7.
• 91%  of  PCV13  recipients  achieved  the  threshold  of  protection  against  Serotype  19A,  a 
predominant invasive pneumococcal serotype in the USA.
• PCV13  offers  the  potential  to  broaden  the  immune  protection  against  invasive  pneumococcal 
disease afforded by the currently licensed pneumococcal conjugate vaccine.
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STUDY DESIGN
Randomised 1:1
PCV13 Group
PCV13: 2, 4 months
MenC: 2,4 months
DTaP-IPV-Hib: 2,3,4 months
PCV7 group
PCV7: 2,4 months
MenC: 2,4 months
DTaP-IPV-Hib: 2,3,4 months
Figure 1: Percentage of participants achieving prespecified antibody concentrations 
after infant series of  concomitant vaccines. Error bars represent 95%C.I.
Figure 4: Systemic reactions within 4 days of vaccination
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Figure 5: Local reactions reported by participants within 4 days of vaccination
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RESULTS
• 278 infants were enrolled; 139 to the PCV13 group (mean age 2.1 months, 56% male) and 139 
to PCV7 group (mean age 2.1 months, 46% male)
• 135 (PCV13) and 132 (PCV7) completed the infant stage of the study
• Immunogenicity  results  for  the  concomitant  vaccines  are  shown  in  Figure  1  (concomitant 
vaccines) and Figures 2 and 3 (PCV13), while PCV13 reactogenicity is shown in Figures 4 and 5
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Figure 3: Percentage of participants in the PCV13 group achieving IgG ≥ 0.35 
mcg/ml for each pneumococcal serotype
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Figure 2: Pneumococcal immunogenicity for the PCV13 group after dose 2 of the 
infant series (IgG GMC)
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• Pneumococcal serotype specific IgG was measured by standardised ELISA with a correlate 
of protection of ≥ 0.35 mcg/ml3